Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down - Here's What Happened

Key Points

• Maravai LifeSciences shares fell sharply, opening at $5.60 versus a prior close of $6.25 and later trading near $5.69.
• Analyst sentiment remains mixed: the stock has an average “Hold” rating and a $5.83 target price, with ratings ranging from “Buy” to “Sell.”
• The company beat quarterly expectations with $0.01 in adjusted EPS versus a projected loss of $0.05 and revenue of $65.84 million versus a $53 million estimate, though it continues to report negative margins and is forecast to post a full-year loss.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MRVI. UBS Group reiterated a "reduce" rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $6.00 target price on shares of Maravai LifeSciences in a research note on Friday, May 8th. Weiss Ratings raised Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 29th. Wells Fargo & Company upped their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a research report on Friday. Finally, Wall Street Zen downgraded shares of Maravai LifeSciences from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $5.83.

Maravai LifeSciences Price Performance

The stock has a market capitalization of $1.51 billion, a PE ratio of -8.23 and a beta of 0.63. The business's 50-day moving average price is $5.95 and its 200 day moving average price is $4.37. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.06. The company had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%. Research analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the company's stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the transaction, the general counsel directly owned 360,767 shares in the company, valued at $1,825,481.02. This represents a 6.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. raised its stake in Maravai LifeSciences by 2.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company's stock valued at $20,595,000 after purchasing an additional 178,445 shares in the last quarter. Mackenzie Financial Corp grew its stake in Maravai LifeSciences by 1.7% in the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company's stock worth $20,148,000 after buying an additional 104,355 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Maravai LifeSciences by 0.9% in the 1st quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company's stock worth $12,069,000 after buying an additional 39,600 shares during the last quarter. Tejara Capital Ltd increased its holdings in shares of Maravai LifeSciences by 23.1% in the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company's stock worth $9,816,000 after buying an additional 566,768 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Maravai LifeSciences by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company's stock valued at $9,259,000 after buying an additional 34,447 shares in the last quarter. Hedge funds and other institutional investors own 50.25% of the company's stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source